Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 7;80(20):1900–1908. doi: 10.1016/j.jacc.2022.08.799

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the American College of Cardiology Foundation. Published by Elsevier.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Cumulative Incidence Plots for Myocarditis 21 Days Following COVID-19 mRNA Vaccines

Cumulative incidence plots for myocarditis 21 days after second dose of COVID-19 messenger RNA (mRNA) vaccine stratified by the type of vaccine, created using the Kaplan-Meier approach. The plot shows a rapid rise in incident myocarditis within the first 7-10 days after second dose for both mRNA vaccines. Comparatively, the cumulative incidence is higher and rises rapidly among mRNA-1273 recipients than BNT162b2 recipients.